JPH058171B2 - - Google Patents
Info
- Publication number
- JPH058171B2 JPH058171B2 JP7632484A JP7632484A JPH058171B2 JP H058171 B2 JPH058171 B2 JP H058171B2 JP 7632484 A JP7632484 A JP 7632484A JP 7632484 A JP7632484 A JP 7632484A JP H058171 B2 JPH058171 B2 JP H058171B2
- Authority
- JP
- Japan
- Prior art keywords
- acetaminophen
- fatty acid
- oil
- composition
- soft capsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 54
- 229960005489 paracetamol Drugs 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 20
- 239000007901 soft capsule Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 15
- 229930195729 fatty acid Natural products 0.000 claims description 15
- -1 polyoxyethylene Polymers 0.000 claims description 15
- 150000004665 fatty acids Chemical class 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 230000001754 anti-pyretic effect Effects 0.000 claims description 4
- 239000002221 antipyretic Substances 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- 239000003925 fat Substances 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 229940083466 soybean lecithin Drugs 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 229940124579 cold medicine Drugs 0.000 claims description 2
- 210000002969 egg yolk Anatomy 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 5
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 4
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- PUHLHLQBIFRKRD-CSKARUKUSA-N 5-methyl-2-[(E)-2-phenylethenyl]-1,3-benzoxazole Chemical compound N=1C2=CC(C)=CC=C2OC=1\C=C\C1=CC=CC=C1 PUHLHLQBIFRKRD-CSKARUKUSA-N 0.000 description 3
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960000896 tipepidine Drugs 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940125716 antipyretic agent Drugs 0.000 description 2
- KSUUMAWCGDNLFK-UHFFFAOYSA-N apronal Chemical compound C=CCC(C(C)C)C(=O)NC(N)=O KSUUMAWCGDNLFK-UHFFFAOYSA-N 0.000 description 2
- 229960004459 apronal Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229960000920 dihydrocodeine Drugs 0.000 description 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 2
- 229940073563 dl- methylephedrine hydrochloride Drugs 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940051020 methylephedrine hydrochloride Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は軟カプセル充填用組成物、更に詳細に
は、アセトアミノフエン又はアセトアミノフエン
配合薬剤の軟カプセル充填用組成物に関する。
アセトアミノフエンは発熱を伴う感冒、炎症性
疾患の解熱剤として、また頭痛、生理痛、筋肉痛
等の鎮痛剤として、単独あるいは他の医薬品と併
用して使用されている。
しかしながら、アセトアミノフエンは斯かる目
的で使用する場合、通常１回の服用量が150〜300
mgと多く、しかも一般に使用されている軟カプセ
ル用基剤に溶解し難いため、これを従来一般に使
用されている油脂又は液状脂肪酸類等の基剤に分
散させて流動性のある軟カプセル用充填剤を得よ
うとすると、アセトアミノフエン１重量部に対し
基剤を1.5〜2.5重量部に使用しなければならない
が、斯くするとカプセルが大型となるかあるいは
１回に服用するカプセル数が多くなり服用に困難
をきたすことを免れなかつた。
一方、総合感冒剤、解熱剤及び鎮痛剤に使用さ
れる他の成分は、その配合量が少ないかあるいは
当該基剤に溶解するため、アセトアミノフエンを
配合しない場合は軟カプセル化が容易である。し
かし、アセトアミノフエンは解熱鎮痛剤として極
めて優れているため、上記薬剤に好んで配合され
ているが、一方ではこれが当該薬剤を軟カプセル
化する際の隘路となつていた。
本発明者は、斯かる難点を解決すべく鋭意研究
の結果、充填用基剤として特定の界面活性剤を添
加した油脂又は液状脂肪酸類を用いれば、少量で
もアセトアミノフエンを均一に分散でき、充填に
も適した流動性を有する軟カプセル充填用組成物
が得られることを見出し、本発明を完成した。
すなわち、本発明は、大豆レシチン、ヨークレ
シチン、ポリオキシエチレン硬化ヒマシ油、ポリ
オキシエチレンモノステアレート、ソルビタン脂
肪酸エステル及びシヨ糖脂肪酸エステルからなる
群から選ばれる界面活性剤の１種又は２種以上を
含有する油脂又は液状脂肪酸類に、アセトアミノ
フエン又はアセトアミノフエン配合薬剤を分散せ
しめた軟カプセル充填用組成物を提供するもので
ある。
本発明において、アセトアミノフエン配合薬剤
に配合される他の医薬品としては、一般に総合感
冒剤、鎮痛剤、解熱剤等に使用されるものは何れ
も使用することができ、例えば臭化水素酸デキス
トロメトルフアン、塩酸メチルエフエドリン、ヒ
ベンズ酸チペピジン、リン酸ジヒドロコデイン等
の鎮咳去痰剤；マレイン酸クロルフエニラミン等
の抗ヒスタミン剤；ビタミンＣ、塩酸チアミン、
リボフラビン等のビタミン剤；無水カフエイン、
アリルイソプロピルアセチル尿素等が挙げられ
る。
また、本発明組成物の基剤に使用される油脂又
は脂肪酸類としては、通常軟カプセル剤に使用さ
れるものは何れも使用することができ、例えば、
ラツカセイ油、ダイズ油、紅花油、トウモロコシ
油、小麦胚芽油、トリ中鎖脂肪酸グリセリン、オ
レイン酸等が挙げられる。
本発明の基剤には、これらの油脂又は脂肪酸類
に特定の上記界面活性剤を含有せしめることが必
要であり、実施例を示す如く、他の界面活性剤で
は目的を達成することができない。この界面活性
剤の量は、その種類によつても異なるが、基剤中
0.1〜80％になるようにするのが好ましい。
アセトアミノフエン又はその配合薬剤は基材１
重量部に対し、0.6〜1.5重量部、特に0.7〜1.3重
量部となるように分散させるのが好ましい。
本発明の軟カプセル充填用組成物は、予め微粉
砕したアセトアミノフエン又はその配合薬剤を当
該基剤に分散させるか、あるいはアセトアミノフ
エン又はその配合薬剤を当該基剤に加え、その中
で微細化する方法によつて製造される。
このようにすると、アセトアミノフエン及びそ
の配合薬剤を少量の基剤に安定に懸濁させること
ができ、この懸濁液は軟カプセルに充填するのに
適した流動性を有する。
次に実施例を挙げて本発明を説明する。
実施例 １
予め微粉砕したアセトアミノフエンを下記第１
表に示す各種界面活性剤を含むトリ中鎖脂肪酸グ
リセリン中に分散させて軟カプセル充填用組成物
を調整し、その流動性を調べた。その結果を第１
表に示す。なお、流動性は、オリフイス径測定器
（小西製作所製）を用いて測定した。すなわち、
当該装置上に設置されているホツパー内に各組成
物を約60gずつ取り、ホツパー下部にある直径
3.15mmの穴から組成物が流れ出す程度を、下記基
準に従つて３段階に評価した。
○：やや粘り気のある均一な懸濁液状を呈し、
連続的に流れ出す。
△：５秒に１滴以上流れ出すが、その流れが連
続的ではない。
×：ペースト状を呈し、全く流れ出さないか、
又は流れ出してもその流れが５秒に１滴未満
である。
また第１表において、比較品の結果は、アセト
アミノフエンの量が基剤に対して0.6重量倍のも
ののみを示した。
The present invention relates to a composition for filling soft capsules, and more particularly to a composition for filling soft capsules of acetaminophen or acetaminophen-containing drugs. Acetaminophen is used alone or in combination with other medicines as an antipyretic for colds and inflammatory diseases accompanied by fever, and as an analgesic for headaches, menstrual pain, muscle pain, and the like. However, when acetaminophen is used for this purpose, the usual dose is 150 to 300.
mg, and it is difficult to dissolve in commonly used soft capsule bases, so it is dispersed in commonly used bases such as oils and fats or liquid fatty acids to fill fluid soft capsules. In order to obtain a drug, it is necessary to use 1.5 to 2.5 parts by weight of the base for 1 part by weight of acetaminophen, but in this case, the capsules become large or the number of capsules to be taken at a time increases. I had no choice but to have difficulty taking the drug. On the other hand, other ingredients used in general cold remedies, antipyretics, and analgesics are easily encapsulated in soft capsules when acetaminophen is not blended, because their blending amounts are small or they dissolve in the base. However, although acetaminophen is extremely excellent as an antipyretic analgesic and is therefore preferably incorporated into the above-mentioned drugs, this has been a bottleneck in encapsulating the drug into soft capsules. As a result of intensive research to solve these difficulties, the present inventor has found that by using oil or fat or liquid fatty acids to which a specific surfactant is added as a filling base, acetaminophene can be uniformly dispersed even in small amounts. The present invention was completed based on the discovery that a soft capsule filling composition having fluidity suitable for filling can be obtained. That is, the present invention provides one or more surfactants selected from the group consisting of soybean lecithin, yoke lecithin, polyoxyethylene hydrogenated castor oil, polyoxyethylene monostearate, sorbitan fatty acid ester, and sucrose fatty acid ester. The present invention provides a composition for filling soft capsules in which acetaminophen or an acetaminophen-containing drug is dispersed in an oil or a liquid fatty acid containing the following. In the present invention, as other pharmaceuticals to be added to the acetaminophen-containing drug, any of those commonly used in common cold medicines, analgesics, antipyretics, etc. can be used, such as dextrohydrobromide. Antitussive and expectorant agents such as metorfan, methylephedrine hydrochloride, tipepidine hibenzate, and dihydrocodeine phosphate; antihistamine agents such as chlorpheniramine maleate; vitamin C, thiamine hydrochloride,
Vitamin preparations such as riboflavin; anhydrous caffeine,
Examples include allylisopropylacetylurea. Furthermore, as the oil or fat or fatty acid used as the base of the composition of the present invention, any oil or fatty acid that is normally used for soft capsules can be used, for example,
Examples include rattan oil, soybean oil, safflower oil, corn oil, wheat germ oil, tri-medium chain fatty acid glycerin, and oleic acid. In the base of the present invention, it is necessary for these oils and fats or fatty acids to contain the above-mentioned specific surfactant, and as shown in the examples, the purpose cannot be achieved with other surfactants. The amount of surfactant in the base material varies depending on the type of surfactant.
It is preferable to set it to 0.1 to 80%. Acetaminophen or its compounded drug is base material 1
It is preferable to disperse it in an amount of 0.6 to 1.5 parts by weight, particularly 0.7 to 1.3 parts by weight. The composition for filling soft capsules of the present invention can be prepared by dispersing pre-pulverized acetaminophen or its compounded drug in the base, or by adding acetaminophen or its compounded drug to the base, and then dispersing the acetaminophen or its compounded drug in the base. Manufactured by a method of In this way, acetaminophen and its compounded drug can be stably suspended in a small amount of the base material, and this suspension has fluidity suitable for being filled into soft capsules. Next, the present invention will be explained with reference to Examples. Example 1 Pre-pulverized acetaminophene was mixed into the following
A composition for filling soft capsules was prepared by dispersing it in tri-medium chain fatty acid glycerin containing the various surfactants shown in the table, and its fluidity was examined. The result is the first
Shown in the table. Note that the fluidity was measured using an orifice diameter measuring device (manufactured by Konishi Seisakusho). That is,
Pour approximately 60g of each composition into the hopper installed on the device, and place it in the diameter at the bottom of the hopper.
The degree to which the composition flowed out from the 3.15 mm hole was evaluated in three grades according to the following criteria. ○: Appears as a slightly sticky and uniform suspension,
flows out continuously. Δ: One or more drops flow out every 5 seconds, but the flow is not continuous. ×: Appears like a paste and does not flow out at all, or
Or even if it flows out, the flow is less than 1 drop every 5 seconds. Also, in Table 1, the results for comparative products are shown only when the amount of acetaminophene is 0.6 times the weight of the base.
【表】
第１表から明らかな如く、比較品はいずれもア
セトアミノフエンの配合量が基剤に対して0.6重
量倍未満でペースト状となり、流動性が全く無く
なつて、軟カプセル充填用としては適さないもの
となつてしまうが、大豆レシチン、ヨークレシチ
ン、ポリオキシエチレン硬化ヒマシ油、ポリオキ
シエチレンモノステアレート、ソルビタン脂肪酸
エステル及びシヨ糖脂肪酸エステルを含む基剤を
使用することにより、基剤に対して0.6重量倍以
上のアセトアミノフエンを配合しても流動性を有
し、軟カプセル充填用として適する懸濁液が得ら
れる。
実施例 ２
下記組成の軟カプセル充填用組成物を調整し
た。
アセトアミノフエン 900mg
アリルイソプロピルアセチル尿素 150mg
無水カフエイン 120mg
大豆レシチン 100mg
ダイズ油 140mg トリ中鎖脂肪酸グリセリン 750mg
2160mg
実施例 ３
下記組成の軟カプセル充填用組成物を調整し
た。
アセトアミノフエン 900mg
マレイン酸クロルフエニラミン 7.5mg
リン酸ジヒドロコデイン 15mg
dl−塩酸メチルエフエドリン 30mg
無水カフエイン 75mg
ヨークレシチン 75mg トリ中鎖脂肪酸グリセリン 1057.5mg
2160mg
実施例 ４
下記組成の軟カプセル充填用組成物を調整し
た。
アセトアミノフエン 900mg
マレイン酸クロルフエニラミン 7.5mg
ヒベンズ酸チペピジン 75mg
dl−塩酸メチルエフエドリン 30mg
無水カフエイン 75mg
ポリオキシエチレン硬化ヒマシ油 200mg トリ中鎖脂肪酸グリセリン 1292.5mg
2580mg
実施例 ５
下記組成の軟カプセル充填用組成物を調整し
た。
アセトアミノフエン 900mg
マレイン酸クロルフエニラミン 7.5mg
ヒベンズ酸チペピジン 75mg
dl−塩酸メチルエフエドリン 60mg
無水カフエイン 75mg
ソルビタン脂肪酸エステル 100mg トリ中鎖脂肪酸グリセリン 1392.5mg
2610mg[Table] As is clear from Table 1, in all comparative products, when the amount of acetaminophene blended was less than 0.6 times the weight of the base, it became paste-like and had no fluidity, making it difficult to use for filling soft capsules. However, by using a base containing soybean lecithin, yoke lecithin, polyoxyethylene hydrogenated castor oil, polyoxyethylene monostearate, sorbitan fatty acid ester, and sucrose fatty acid ester, the base Even if 0.6 times or more by weight of acetaminophen is added to the suspension, a suspension that has fluidity and is suitable for filling soft capsules can be obtained. Example 2 A composition for filling soft capsules having the following composition was prepared. Acetaminophen 900mg Allylisopropylacetylurea 150mg Anhydrous caffein 120mg Soybean lecithin 100mg Soybean oil 140mg Tri-medium chain fatty acid glycerin 750mg 2160mg Example 3 A composition for filling soft capsules having the following composition was prepared. Acetaminophen 900mg Chlorpheniramine maleate 7.5mg Dihydrocodeine phosphate 15mg dl-methylephedrine hydrochloride 30mg Anhydrous caffein 75mg Yoclecithin 75mg Tri-medium chain fatty acid glycerin 1057.5mg 2160mg Example 4 A composition for filling soft capsules having the following composition was prepared. It was adjusted. Acetaminophen 900mg Chlorpheniramine maleate 7.5mg Tipepidine hibenzate 75mg dl-methylephedrine hydrochloride 30mg Anhydrous caffein 75mg Polyoxyethylene hydrogenated castor oil 200mg Tri-medium chain fatty acid glycerin 1292.5mg 2580mg Example 5 Soft capsule filling with the following composition A composition for use was prepared. Acetaminophen 900mg Chlorpheniramine maleate 7.5mg Tipepidine hibenzate 75mg dl-methylefedrine hydrochloride 60mg Anhydrous caffein 75mg Sorbitan fatty acid ester 100mg Tri-medium chain fatty acid glycerin 1392.5mg 2610mg
Claims (1)
エチレン硬化ヒマシ油、ポリオキシエチレンモノ
ステアレート、ソルビタン脂肪酸エステル及びシ
ヨ糖脂肪酸エステルからなる群から選ばれる界面
活性剤の１種又は２種以上を含有する油脂又は液
状脂肪酸類に、アセトアミノフエン又はアセトア
ミノフエン配合薬剤を分散せしめたことを特徴と
する軟カプセル充填用組成物。 ２ 当該油脂又は液状脂肪酸類１種重量部に対
し、アセトアミノフエン又はアセトアミノフエン
配合薬剤が0.6〜1.5重量部である特許請求の範囲
第１項記載の組成物。 ３ アセトアミノフエン配合薬剤が総合感冒剤、
鎮痛剤又は解熱剤である特許請求の範囲第１項又
は第２項記載の組成物。[Scope of Claims] 1. One or two surfactants selected from the group consisting of soybean lecithin, yolk lecithin, polyoxyethylene hydrogenated castor oil, polyoxyethylene monostearate, sorbitan fatty acid ester, and sucrose fatty acid ester. A composition for filling soft capsules, characterized in that acetaminophen or an acetaminophen-containing drug is dispersed in an oil or fat or liquid fatty acid containing the above. 2. The composition according to claim 1, wherein the amount of acetaminophen or acetaminophen-containing drug is 0.6 to 1.5 parts by weight per part by weight of the oil or fat or liquid fatty acid. 3 Drugs containing acetaminophen are general cold medicines,
The composition according to claim 1 or 2, which is an analgesic or an antipyretic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7632484A JPS60218318A (en) | 1984-04-16 | 1984-04-16 | Composition for filling in soft capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7632484A JPS60218318A (en) | 1984-04-16 | 1984-04-16 | Composition for filling in soft capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60218318A JPS60218318A (en) | 1985-11-01 |
| JPH058171B2 true JPH058171B2 (en) | 1993-02-01 |
Family
ID=13602180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7632484A Granted JPS60218318A (en) | 1984-04-16 | 1984-04-16 | Composition for filling in soft capsule |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60218318A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2537658B2 (en) * | 1987-04-13 | 1996-09-25 | 小野薬品工業株式会社 | Novel formulation containing ester or amide as active ingredient |
| PL1660047T3 (en) | 2003-08-13 | 2014-05-30 | Biocon Ltd | Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
| JP6214395B2 (en) * | 2010-08-10 | 2017-10-18 | アール．ピー． シェーラー テクノロジーズ エルエルシー | Method for producing stable soft gel capsules containing microencapsulated probiotic bacteria |
| JP7224008B1 (en) * | 2022-08-30 | 2023-02-17 | 株式会社東洋新薬 | oral composition |
-
1984
- 1984-04-16 JP JP7632484A patent/JPS60218318A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60218318A (en) | 1985-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2856817B2 (en) | Pharmaceutical composition | |
| FI96095B (en) | Process for the preparation of drug preparations with depot properties | |
| SI9111227A (en) | Pharmaceutical composition with an active agent Flupirtine for treating muscle tension | |
| NO328863B1 (en) | Pharmaceutical preparation for oral administration containing omeprazole | |
| Kluk et al. | Application properties of oral gels as media for administration of minitablets and pellets to paediatric patients | |
| EP0152292A2 (en) | Acetaminophen gelatin capsules | |
| JP2003525893A (en) | Novel self-emulsifying drug delivery system | |
| JPH069381A (en) | Soft capsule containing ibuprofen | |
| JPH0816051B2 (en) | Sustained release suppositories | |
| US5175002A (en) | Amantadine hydrochloride syspension with enhanced dissolution characteristics for use in soft gelatin capsules | |
| JP3496158B2 (en) | Gelatin capsule preparation containing tranexamic acid | |
| JPH058171B2 (en) | ||
| JPS6092214A (en) | Composition for filling soft capsule | |
| EP0109281A1 (en) | Compositions comprising flurbiprofen or ibuprofen | |
| JPS6345366B2 (en) | ||
| EP0279519A1 (en) | Pharmaceutical compositions containing salts of ibuprofen in a hydrophilic carrier | |
| IE912201A1 (en) | Amantadine hydrochloride suspension with enhanced¹dissolution characteristics for use in soft gelatin capsules | |
| SE452550B (en) | TABLET WITH DELAYED RELEASE OF THEOPHYLLINE | |
| JPH07549B2 (en) | Composition for filling soft capsules | |
| JPS61200909A (en) | Long-acting composition for filling in capsule | |
| JP2001048809A (en) | Sustained release suppository containing polyglyceryl behenate | |
| CA2641450A1 (en) | Spill resistant antibiotic formulations | |
| JPH0617305B2 (en) | Chemical solution for filling soft capsules | |
| JPH06298667A (en) | Sustained release suppository | |
| JPS6237602B2 (en) |